TYK2 Inhibitor Deucravacitinib up for FDA Review for Psoriatic Arthritis

Published Date: 07 Aug 2025

Bristol Myers Squibb's deucravacitinib shows promise as a safe, effective treatment for active psoriatic arthritis, pending FDA approval by March 2026.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot